MiR‑425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy
MiR‑425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy
复制标题
DOI：
10.1186/s12967-018-1647-8
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
徐开林
中科院分区：
文献类型：
--
作者：
杨晨;邵婷婷;张慧慧;张宁汉;施小宁;刘雪娇;姚瑶;徐林艳;朱升云;曹江;程海;闫志凌;李振宇;牛铭山;徐开林
Background: Acute myeloid leukemia (AML) is a highly heterogeneous disease. MicroRNAs function as important.biomarkers in the clinical prognosis of AML..Methods: This study identified miR-425 as a prognostic factor in AML by screening the TCGA dataset. A total of 162.patients with AML were enrolled for the study and divided into chemotherapy and allogeneic hematopoietic stem.cell transplantation (allo-HSCT) groups..Results: In the chemotherapy group, patients with high miR-425 expression had significantly longer overall survival.(OS) and event-free survival (EFS) compared with patients with low miR-425 expression. In multivariate analyses, high.miR-425 expression remained independently predictive of a better OS (HR = 0.502, P = 0.005) and EFS (HR = 0.432,.P = 0.001) compared with patients with low miR-425 expression. Then, all patients were divided into two groups.based on the median expression levels of miR-425. Notably, the patients undergoing allo-HSCT had significantly better.OS (HR = 0.302, P < 0.0001) and EFS (HR = 0.379, P < 0.0001) compared with patients treated with chemotherapy.in the low-miR-425-expression group. Mechanistically, high miR-425 expression levels were associated with a profile.significantly involved in regulating cellular metabolism. Among these genes, MAP3K5, SMAD2, and SMAD5 were.predicted targets of miR-425..Conclusions: The expression of miR-425 may be useful in identifying patients in need of strategies to select the optimal.therapy between chemotherapy and allo-HSCT treatment regimens. Patients with low miR-425 expression may.consider early allo-HSCT.
